Rapport Therapeutics EBIT Margin 2023-2025 | RAPP

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Rapport Therapeutics ebit margin from 2023 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Rapport Therapeutics ebit margin from 2023 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$225.3B
Amgen (AMGN)	$164.8B
Gilead Sciences (GILD)	$144.5B
Vertex Pharmaceuticals (VRTX)	$120.6B
Bristol Myers Squibb (BMY)	$98.6B
CSL (CSLLY)	$85.4B
GSK (GSK)	$77.7B
Regeneron Pharmaceuticals (REGN)	$60.8B
Alnylam Pharmaceuticals (ALNY)	$42.9B
Argenex SE (ARGX)	$36.2B
BioNTech SE (BNTX)	$27.7B
Royalty Pharma (RPRX)	$20.6B
Insmed (INSM)	$19.7B
Biogen (BIIB)	$19.3B
Illumina (ILMN)	$17.3B
Genmab (GMAB)	$15B
Genmab (GNMSF)	$15B
Incyte (INCY)	$13.6B
Moderna (MRNA)	$13.2B
Exelixis (EXEL)	$12.4B
QIAGEN (QGEN)	$11.5B
BioMarin Pharmaceutical (BMRN)	$11.3B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.2B
Bio-Techne Corp (TECH)	$9.2B
Exact Sciences (EXAS)	$9.1B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Legend Biotech (LEGN)	$8B
Roivant Sciences (ROIV)	$7.9B